Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta Rhecogen , a subsidiary focused on mRNA vaccines of the infectious diseases, launched the world's first lyophilized mRNA vaccine TAIZHOU, China, Jan. 17, 2022 /PRNewswire/ The.
/PRNewswire/ The Philippines has approved Recombinant Two-Component COVID-19 Vaccine (ReCOV) developed by Jiangsu Recbio Technology Co., Ltd. ("Recbio") for.